The 8 most recent market catalysts affecting $AQST, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 75
Aquestive Therapeutics Resubmits FDA Application for Pocket-Sized Allergy Treatment
Aquestive Therapeutics has officially resubmitted its New Drug Application for Anaphylm to the FDA, addressing the issues raised in a previous Complete Response Letter (CRL). This …
Sep 17, 2026
Corporate Catalyst
Neutral
Impact 85
Aquestive Therapeutics Announces Resubmission Of NDA To FDA For Anaphylm Sublingual Film For Type I Allergic Reactions
This headline is a significant corporate catalyst for Aquestive Therapeutics (AQST). The resubmission of the NDA for Anaphylm indicates that the company has addressed previous FDA …
Aug 24, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target
This filing indicates that HC Wainwright & Co. analyst Raghuram Selvaraju has reaffirmed his 'Buy' rating and $10 price target for Aquestive Therapeutics (AQST). This is a continua…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 75
Aquestive Therapeutics Q2 EPS $(0.18) Misses $(0.12) Estimate, Sales $13.819M Beat $11.418M Estimate
This headline presents a classic mixed bag for Aquestive Therapeutics (AQST). The substantial revenue beat indicates strong underlying demand for their products, which is a positiv…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 55
Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $50.584M Est
Aquestive Therapeutics (AQST) has affirmed its FY2026 sales guidance, keeping it within the previously stated range of $46.000 million to $50.000 million. This is a routine update,…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 75
Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study
Aquestive Therapeutics (AQST) has reported successful human factors and pharmacokinetic studies for Anaphylm, their severe allergy treatment. These studies directly address the iss…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 85
Aquestive Therapeutics shares are trading higher after the company announced results from its human factors validation study and pharmacokinetic study for Anaphylm sublingual film
The positive human factors validation and pharmacokinetic study results for Anaphylm are a significant corporate catalyst for Aquestive Therapeutics. This data suggests the subling…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 75
Aquestive Says Anaphylm Human Factors Study Cut Median Pouch-Opening Time To 3 Seconds From 17, With NDA Resubmission On Track For Q3 2026
This headline is a significant positive catalyst for Aquestive (AQST). The dramatic reduction in pouch-opening time for Anaphylm addresses a key concern for a life-saving medicatio…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.